- Home
- ENTA vs RDCM Comparison
ENTA vs RDCM Comparison
Compare ENTA & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- RDCM
- Stock Information
- Founded
- ENTA 1995
- RDCM 1985
- Country
- ENTA United States
- RDCM Israel
- Employees
- ENTA N/A
- RDCM N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- RDCM Computer peripheral equipment
- Sector
- ENTA Health Care
- RDCM Technology
- Exchange
- ENTA Nasdaq
- RDCM Nasdaq
- Market Cap
- ENTA 154.0M
- RDCM 179.7M
- IPO Year
- ENTA 2013
- RDCM 1997
- Fundamental
- Price
- ENTA $5.10
- RDCM $11.28
- Analyst Decision
- ENTA Buy
- RDCM Strong Buy
- Analyst Count
- ENTA 4
- RDCM 2
- Target Price
- ENTA $17.25
- RDCM $15.00
- AVG Volume (30 Days)
- ENTA 266.6K
- RDCM 26.7K
- Earning Date
- ENTA 05-05-2025
- RDCM 05-14-2025
- Dividend Yield
- ENTA N/A
- RDCM N/A
- EPS Growth
- ENTA N/A
- RDCM 79.17
- EPS
- ENTA N/A
- RDCM 0.43
- Revenue
- ENTA $66,590,999.00
- RDCM $61,009,000.00
- Revenue This Year
- ENTA N/A
- RDCM $14.93
- Revenue Next Year
- ENTA N/A
- RDCM $10.74
- P/E Ratio
- ENTA N/A
- RDCM $26.23
- Revenue Growth
- ENTA N/A
- RDCM 18.23
- 52 Week Low
- ENTA $4.09
- RDCM $8.52
- 52 Week High
- ENTA $17.24
- RDCM $15.98
- Technical
- Relative Strength Index (RSI)
- ENTA 43.45
- RDCM 47.85
- Support Level
- ENTA $4.55
- RDCM $9.88
- Resistance Level
- ENTA $5.29
- RDCM $11.34
- Average True Range (ATR)
- ENTA 0.47
- RDCM 0.66
- MACD
- ENTA 0.06
- RDCM 0.04
- Stochastic Oscillator
- ENTA 63.96
- RDCM 68.97
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.